Hertzel C. Gerstein

Jan 13, 2025 | thelancet.com | Hertzel C. Gerstein

aPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton L8S 4K1, ON, CanadabUniversity of Bordeaux, INSERM, BMC, U1034, Pessac, FrancePublication History:Published January 13, 2025DOI: 10.1016/S2213-8587(24)00317-6Also available on ScienceDirectCopyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. FREE with registration!Log in or register to access the full article.

Sep 16, 2024 | dom-pubs.onlinelibrary.wiley.com | Hertzel C. Gerstein |Stefano Del Prato |Renato D. Lopes |Richard E. Pratley

1 BACKGROUND/CONTEXT Glucagon-like-peptide-1 receptor agonists (GLP-1 RA) lower HbA1c by promoting insulin secretion in response to elevated glucose (the incretin effect).1, 2 They also slow gastric emptying; reduce appetite, weight, blood pressure, low-density lipoprotein (LDL) cholesterol and serious health outcomes3; and increase heart rate and pancreatic enzymes. The degree to which these nonglycaemic effects mediate their glycaemic effects remains unclear.

Mar 27, 2024 | thelancet.com | Hertzel C. Gerstein |Marie Pigeyre

Statins cause a moderate dose-dependent increase in new diagnoses of diabetes that is consistent with a small upwards shift in glycaemia, with the majority of new diagnoses of diabetes occurring in people with baseline glycaemic markers that are close to the diagnostic threshold for diabetes.

Mar 27, 2024 | thelancet.com | Hertzel C. Gerstein |Marie Pigeyre

Statins cause a moderate dose-dependent increase in new diagnoses of diabetes that is consistent with a small upwards shift in glycaemia, with the majority of new diagnoses of diabetes occurring in people with baseline glycaemic markers that are close to the diagnostic threshold for diabetes.